42C — IX Biopharma Income Statement
0.000.00%
Last trade - 00:00
- SG$26.89m
- SG$26.81m
- SG$5.91m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.671 | 0.985 | 1.75 | 14.4 | 5.91 |
Cost of Revenue | |||||
Gross Profit | -0.529 | -0.587 | -0.382 | 12.3 | 2.32 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.9 | 11.5 | 9.98 | 18.5 | 15.6 |
Operating Profit | -13.3 | -10.5 | -8.23 | -4.1 | -9.71 |
Net Income Before Taxes | -13.3 | -10.5 | -8.23 | -4.1 | -9.71 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.2 | -10.5 | -8.23 | -4.6 | -9.62 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -2.99 | -10.5 | -8.23 | -4.6 | -9.62 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.99 | -10.5 | -8.23 | -4.6 | -9.62 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.02 | -0.016 | -0.012 | -0.006 | -0.013 |